This is a case report of a 5.6 cm glomangioma supplied by the femoral profunda artery in a 66-year-old male patient with severe peripheral artery disease. The patient complained of discomfort and mild pain at the place of the lesion and an accelerated growth rate in the last two months. A nodular mass located laterally on the left foot, elastic, covered with a thin skin, and mobile, was noted on the clinical exam. Doppler exam demonstrated an active vascular supply. CT angiography showed a femoral profunda artery blood supply and a severe asymptomatic bilateral peripheral artery disease (PAD). The lesion was removed entirely by surgery. A microscopy exam revealed a glomangioma. After surgery, the patient recovered unevenly. However, the patient experienced wound-healing issues that resolved after four weeks of surgery. Although the patient’s PAD was severe, the lesion presented with a burst in dimensions weeks before surgery.

Peripheral artery disease (PAD) is associated with substantial impairment in functional capacity and health-related quality of life (QoL), particularly in patients with symptomatic lower-extremity disease. Although endovascular revascularization is primarily intended to restore arterial perfusion and relieve ischemic symptoms, its short-term impact on patient-reported health status remains clinically relevant. This prospective pre–post study evaluated changes in QoL one month after lower-extremity arterial stenting in 108 patients with PAD. Health-related QoL was assessed using the 36-Item Short Form Health Survey (SF-36) before stenting and at the one-month follow-up, with each patient serving as their own comparator. Changes across SF-36 domains were analyzed to characterize the magnitude and pattern of early patient-reported recovery. Significant improvements were observed after stenting, with the most pronounced changes involving pain, physical functioning, and general health perception. Social functioning also improved, although to a lesser extent. Patients with poorer baseline health status and greater symptom burden tended to demonstrate larger improvements, suggesting that baseline functional impairment may influence the magnitude of perceived benefit after revascularization. Overall, lower-extremity arterial stenting was associated with meaningful short-term improvements in health-related QoL in patients with PAD, particularly in domains related to pain and physical function. These findings support the value of incorporating patient-reported outcomes alongside conventional vascular endpoints when evaluating early outcomes after peripheral endovascular intervention.

Oncology and cardiology use paclitaxel, a powerful cell-division inhibitor. Paclitaxel-eluting coated metal stents in oncology prevent tumor growth by modulating proliferation, apoptosis, and angiogenesis. Paclitaxel-eluting stents reduce in-stent restenosis and maintain arterial patency in cardiology. Paclitaxel encapsulated in liposomes improves targeted administration, pharmacokinetics, and therapeutic efficacy. Liposome-loaded paclitaxel has a stronger anti-tumor effect than standard formulations. Paclitaxel plus sirolimus in a stent may synergistically prevent restenosis and inhibit tumors. Liposomal formulations with supplemental medications offer promising prospects for improving therapeutic accuracy and efficacy. Liposomal paclitaxel enhances targeted drug delivery, which may improve cancer treatment and cardiovascular treatments such as drug-eluting stents and drug-coated balloons in interventional radiology. Advanced delivery technologies have changed paclitaxel drug delivery methods for therapeutic use by overcoming its low solubility and systemic toxicity. Nanocrystals and liposomes enable high drug loading and precise targeted delivery, and, by eliminating toxic solvents such as Cremophor EL, they improve the safety and efficacy of cancer therapy.